X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Great Point Partners Acquires Lyocontract – A German CDMO

Content Team by Content Team
18th June 2024
in Drug Development, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

On a mission so as to debut the life sciences companies on an international stage, Great Point Partners, the healthcare investment firm, is making a play in terms of a private German contract development and manufacturing organization, Lyocontract.

Great Point on June 13 went on to reveal that it has gone ahead and acquired Ilsenburg, which is Germany’s Lyocontract, which apparently has been into drug development as well as production business since 207.

It is well to be noted that Lyocontract happens to function out of a single facility that goes on to give out aseptic liquid filling, freeze-drying as well as packaging services. The company specialises in the liquid and freeze-dried injectable drugs manufacturing that happen to be shipped across the world in terms of both commercial as well as clinical use.

Lyocontract’s production plant, which happens to cater to customers across Germany and even beyond was built between 2010 and 2011 and went on to receive the manufacturing license in 2012, as per the website of the company.

Significantly, Lyomark Pharma went on to become the majority stakeholder in Lyocontract in August 2017, with both companies being privately held and would continue to be managed in an independent way. Notably, this acquisition deal marks the first investment to be sourced as well as implemented by the London-based European team of Great Point, which looks forward to helping growing healthcare companies go ahead and establish an international presence and also enter the US market.

Great Point’s senior vice president, David Slattery, remarked in a statement that Lyocontract happens to have a very strong track record of offering highly specialized as well as critically significant manufacturing services to pharmaceutical companies, thereby getting a very powerful mix of experience, expertise, and tech capacities across all of its partnerships. He adds that this investment highlights GPPs bent on backing some really exceptional as well as proven management teams within businesses that have a competitive edge.

With this buyout, Lyocontract as well as Great Point look forward to scaling up the CDMO contract manufacturing capacities as well as distribution reach, said Tino Galgon, the CEO of Lyocontract.

As a matter of fact, Great Point has gone on to make numerous contract manufacturing investments in the years which have gone by. In the first half of 2022, the group went on to pay an undisclosed amount so as to pick a Performance Cell Manufacturing CDMO based in San Diego. As part of this deal, Performance Cell went ahead and rebranded itself to Cellipoint Bioservices and at the same time announced a range of changes within its leadership.

Before that, Great Point went on to invest $22 million in Bionova in 2019, to be exact, with the cash being used to fund the CDMO construction of a 36,000 sq.ft. biologics plant based in California’s Fremont.

Previous Post

Transforming In 2024 & Beyond - Prefilled Syringes Market

Next Post

Current E&L Issues And How Parenteral Packaging Is Evolving

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Current E&L Issues And How Parenteral Packaging Is Evolving

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In